735 related articles for article (PubMed ID: 8796806)
1. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
2. Serum granulocyte macrophage colony stimulating factor (GM-CSF) in gestational trophoblastic diseases.
Shaarawy M; el-Shobokshy AS; el-Noury AI
Cytokine; 1995 Feb; 7(2):171-5. PubMed ID: 7540057
[TBL] [Abstract][Full Text] [Related]
3. Angiogenin and gestational trophoblastic tumors, a promising prognostic marker.
Shaarawy M; El-Mallah SY; Sheiba M
Clin Chem Lab Med; 2003 Mar; 41(3):306-10. PubMed ID: 12705339
[TBL] [Abstract][Full Text] [Related]
4. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
5. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free beta-subunit, a reliable marker of placental site trophoblastic tumors.
Cole LA; Khanlian SA; Muller CY; Giddings A; Kohorn E; Berkowitz R
Gynecol Oncol; 2006 Aug; 102(2):160-4. PubMed ID: 16631918
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
7. Detection of hCG in trophoblastic disease. The USA hCG reference service experience.
Cole LA; Butler S
J Reprod Med; 2002 Jun; 47(6):433-44. PubMed ID: 12092011
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of macrophage colony-stimulating factor in trophoblastic disease.
Kohorn EI; Kacinski BM; Stanley ER
Gynecol Oncol; 2001 Mar; 80(3):383-6. PubMed ID: 11263936
[TBL] [Abstract][Full Text] [Related]
9. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
10. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.
Cole LA; Khanlian SA; Giddings A; Butler SA; Muller CY; Hammond C; Kohorn E
Gynecol Oncol; 2006 Aug; 102(2):165-72. PubMed ID: 16631243
[TBL] [Abstract][Full Text] [Related]
11. Serum SP1, hPL and beta-hCG levels in trophoblastic diseases.
Zhang WY; Yen GL
Chin Med J (Engl); 1991 Dec; 104(12):995-8. PubMed ID: 1723674
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
13. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia.
Cole LA; Butler SA; Khanlian SA; Giddings A; Muller CY; Seckl MJ; Kohorn EI
Gynecol Oncol; 2006 Aug; 102(2):151-9. PubMed ID: 16631241
[TBL] [Abstract][Full Text] [Related]
14. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
16. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
17. Monitoring therapy in trophoblastic diseases by radioimmunoassay of pregnancy-specific beta 1-glycoprotein and the beta subunit of human chorionic gonadotropin.
Than GN; Csaba IF; Bohn H; Szabó DG; Szalmásy M; Menczer G
Oncodev Biol Med; 1982; 3(4):315-23. PubMed ID: 6291007
[TBL] [Abstract][Full Text] [Related]
18. Measurement of CA-125 in trophoblastic disease.
Kohorn EI
Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of determining chorionic gonadotropin and trophoblastic beta 1-glycoprotein in trophoblastic disease].
Grinevich IuA; Tatarinov IuS; Iugrinova LG; Olefirenko GA; Dotsenko IuS
Vopr Onkol; 1981; 27(12):19-23. PubMed ID: 6275607
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 gene promoter polymorphisms in women with gestational trophoblastic diseases.
Kashef MA; Dehaghani AS; Naeimi S; Fattahi MJ; Ghaderi A
J Reprod Med; 2008 Nov; 53(11):853-9. PubMed ID: 19097518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
